Purpose. Recently, the strong antiviral activity of an Actinobacillus pleuropneumoniae (App) culture supernatant against porcine reproductive and respiratory syndrome virus (PRRSV) was discovered. Following this finding, the objective of the present study was to understand how the App culture supernatant inhibits PRRSV replication in its natural targeted host cells, i.e. porcine alveolar macrophages (PAMs).
INTRODUCTION
Porcine reproductive and respiratory syndrome (PRRS) is a worldwide endemic disease, which causes significant economic losses in pig-producing countries. The causative agent, PRRS virus (PRRSV), belongs to the family Arteriviridae of the Nidovirales order. Following the discovery of several new arteriviruses, a new taxonomic classification was recently proposed [1] . PRRSV is an enveloped singlestranded positive-sense RNA virus of approximately 15 kb in length that encodes for at least 11 ORFs [2] . It has a strongly restricted cell tropism for the monocyte-macrophage lineage in vivo. In fact, in its natural host, the primary cells targeted by PRRSV are the fully differentiated porcine alveolar macrophages (PAMs), which are often used for in vitro study [3] [4] [5] [6] . The only two continuous cell lines nongenetically modified able to fully replicate PRRSV are: African green monkey kidney cell line MA-104 and its derivatives like MARC-145 [7] and, the newly permissive reported St-Jude porcine lung (SJPL) cells, which were found to be of monkey origin [8, 9] .
Following PRRSV entry and release of its viral genome into the cytoplasm, the PRRSV ORF1 is translated. Then, the resulting non-structural proteins trigger the formation of the replication-transcription complex, which allows double membrane vesicles to initiate the genome replication and transcription process [10] [11] [12] . The genome replication is produced by the continuous synthesis of negative (À) fulllength RNA strands using the positive genomic RNA [(+) gRNA] as a template. Then, the (À) RNA strands will lead to the formation of new (+) gRNAs [13] . The genome transcription process leads to the synthesis of a nested set of sub-genomic mRNAs (sg mRNAs). According to a model proposed by Sawicki and collaborators [14] , the generation of these sg mRNAs originates from a discontinuous RNA synthesis process, where (À) sgRNA strands are produced and are subsequently used as templates for sg mRNA synthesis.
Current management strategies, which focus on the prevention of PRRSV infection (ex. biosecurity measures, surveillance, whole herd depopulation and repopulation, and herd closure [15] ) and vaccination using commercially available modified live-attenuated vaccines or autogenous-killed vaccines, have mostly been demonstrated to be inadequate for long-term control of PRRS [16] . This prompts the search for novel strategies to control PRRSV infection. In this sense, recently published works have discovered natural compounds with antiviral activities against PRRSV, such as macrolides [17] , N-acetylpenicillamine [18] , Cryptoporus volvatus extract [19] , morpholino oligomer [16, 20] , Matrine [21] , sodium tanshinone IIA sulfonate [22] and flavaspidic acid AB [23] . Each of these compounds inhibits PRRSV replication differently. For instance, the flavaspidic acid AB inhibits PRRSV internalization and cell-to-cell virus transmission, probably by the induction of type I IFNs [23] . Sun and colleagues demonstrated that Matrine inhibits N protein expression and has anti-apoptotic functions [21] . Moreover, Cryptoporus volvatus extract was demonstrated to inhibit PRRSV infection in vitro and in vivo, probably by the direct inhibition of PRRSV polymerase activity [19] . However, and despite these efforts, there are no effective commercially available drugs to prevent PRRSV infection.
Our previous work revealed that the cell culture supernatant of the Actinobacillus pleuropneumoniae (App) mutant strain (AppDapxICDapxIIC) possesses an antiviral activity against PRRSV in infected SJPL and PAM cells, but this antiviral activity was not observed in infected MARC-145 cells [24] . It was the first time that a bacterial antiviral effect against PRRSV in vitro was reported. Thereafter, our team has investigated the mechanisms involved in the antiviral activity displayed by the App culture supernatant. It was found that the App culture supernatant was able to induce cell cycle arrest at the G2/M-phase in PRRSV-infected SJPL cells, such as two other G2/M-phase cell cycle inhibitors, which are also inhibiting PRRSV replication [25] . Unfortunately, during our previous investigation, the effect of the App culture supernatant on PAM cell cycle could not be investigated because unlike SJPL cells, PAM cells do not replicate. Therefore, it is crucial to investigate the antiviral activity displayed by the App culture supernatant in a more pathogenic relevant model, i.e. PRRSV-infected PAM cells. Results showed that the App culture supernatant blocks PRRSV replication prior to its first cycle of genome replication and transcription in infected PAM and SJPL cells. Following proteomic analyses, data suggest that the early App culture supernatant antiviral effect against PRRSV in infected PAM cells takes place via the activation of cofilin and thus actin depolymerization, which probably affects PRRSV endocytosis.
METHODS Cells
MARC-145 and SJPL cell lines were maintained as previously described [24] . The SJPL cell line was kindly provided by Dr R.G. Webster [8] . PAM cells were obtained from lungs of 2-to 14-week-old pigs as previously described [9, 24] . PAM cells were cultured for 24 h in complete Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, GibcoBRL) complemented with 10 % fetal bovine serum, 2 mM L-glutamine, 10 mM HEPES, 1Â non-essential amino acids, 2.5 µg ml À1 amphotericin B, 0.5 IU ml À1 penicillin, 0.5 µg ml À1 streptomycin and 50 µg ml À1 gentamicin (Wisent) [24] . All cells were cultured and infected at 37 C in 5 % CO 2 atmosphere.
Viral and bacterial strains
The PRRSV strain used in this study was the Canadian genotype II reference strain IAF-Klop and the virus stocks were obtained as previously described [9] . The App strain used was the mutant MBHPP147 (AppDapxICDapxIIC) from the strain S4074, which is a serotype 1 reference strain. This mutant produces non-active ApxI and ApxII toxins and was kindly provided by Ruud P.A.M. Segers (MSD Animal Health). The App strain was cultured on brain heart infusion (BHI) broth and/or agar (Oxoid) supplemented with 15 µg ml À1 nicotinamide adenine dinucleotide (NAD) at 37 C in 5 % CO 2 . The App culture supernatant was obtained as previously described [24] .
Infection of cells
Cells were infected, as previously described [24] , with PRRSV IAF-Klop strain at 0.5 m.o.i. and incubated in DMEM without serum or other additives during a period of 4 h, then a soft washing step using PBS was performed. Thereafter, the App culture supernatant or complete medium in the case of controls were added (protocol 1). Another infection protocol was tested to determine if the App culture supernatant added prior to PRRSV infection had an impact on the results (protocol 2). Cells were pretreated with the bacterial supernatant (or medium for controls) during a 2 h period, followed by PRRSV infection at 0.5 m.o.i. in DMEM without serum or other additives for 4 h, then a soft wash step with PBS was performed and finally, the App culture supernatant or the complete medium were added. Both infection protocols were used throughout this study unless specified.
Cell viability and mortality 2Â10 5 PAM cells well À1 were incubated during a 24 h period. Afterwards, cells were infected with PRRSV using protocol 1 and incubated in the presence of the App culture supernatant or complete medium during a 48 h period. Cell viability was measured with CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) at 52 h postinfection (p.i.). Cellular mortality was determined using the lactate dehydrogenase (LDH)-measuring CytoTox 96 nonradioactive cytotoxicity assay (Promega). Mechanically lysed cells were used as a 100 % mortality positive control. For both methods, non-infected cells were used as a negative control and the absorbance was measured at 490 nm with a SynergyTM HT multi-detection microplate reader (Biotek). Both tests were repeated three times. ] (Sigma-Aldrich). Total cellular RNA was extracted from cells using Trizol reagent (Invitrogen). RNA quantification was performed using NanoDrop ND-1000 (NanoDrop Technologies). Then, 1 µg of total RNA was reverse-transcribed using the QuantiTect reverse transcription kit (Qiagen). Specific cDNA targets were amplified using the SsoFast EvaGreenW Supermix kit (Bio-Rad) in the Bio-Rad CFX-96 sequence detector apparatus. The PCR amplification program for all cDNA targets consisted of an enzyme activation step of 3 min at 98 C, followed by 40 cycles of a denaturing step for 2 s at 98 C and an annealing/ extension step for 5 s at 57 C. The primer pairs used for the amplification of type I IFNs and IFN-g in PAM were: IFNa: F 5¢-ACTCCATCCTGGCTGTGAGGAAAT-3¢ and R 5¢-TCTGTCTTGCAGGTTTGTGGAGGA-3¢; IFN-b: F 5¢-C TCTCCTGATGTGTTTCTCC-3¢ and R 5¢-GTTCATCCTA TCTTCGAGGC-3¢; IFN-g: F 5¢-GAGCCAAATTGTCTCC TTCTAC-3¢ and R 5¢-CGAAGTCATTCAGTTTCCCAG-3¢. The porcine b-actin and monkey b-actin genes' amplification were performed using the primers F 5¢-ACCAC TGGCATTGTCATGGACTCT-3¢ and R 5¢-ATCTTCA TGAGGTAGTCGGTCAGG-3¢; and F 5¢-GGCATCCA TGAAACTACCTTC-3¢ and R 5¢-AGGGCAGTAATCTCC TTCTG-3¢, respectively. Peptidylprolyl isomerase A (PPIA) and beta-2 microglobulin (B2M) were used as normalizing genes in PAM and SJPL/MARC-145 cells, respectively, and were amplified using the following primers pairs: PPIA: F 5¢-TGCAGACAAAGTTCCAAAGACAG-3¢ and R 5¢-GCCACCAGTGCCATTATGG-3¢; B2M [9] : F 5¢-GTGCTA TCTCCACGTTTGAG-3¢ and R 5¢-GCTTCGAGTGCAA-GAGATTG-3¢. Primer sequences were designed from the NCBI GenBank mRNA sequences using web-based software primerquest (Integrated DNA Technologies). Uninfected cells were used as the calibrator reference in the analysis. Differences in quantification between groups were calculated using the 2 ÀDDCt method. These experiments were repeated three times in duplicate.
PRRSV genome replication/transcription kinetics 4Â10 6 PAM cells well À1 and 5Â10 5 SJPL or MARC-145 cells well À1 were incubated during a period of 24 h, and were, thereafter, infected with PRRSV with or without the App culture supernatant. At different times p.i., samples were collected to perform a specific RT-qPCR assay. The strategy used to determine PRRSV genome replication and transcription has already been published, however, new primers were designed for this study [26] . Briefly, total RNAs were extracted from cells and quantified as described above. Then, 1.5 µg of total RNA was reverse-transcribed using M-MLV reverse transcriptase (Invitrogen). In total, 2 pmol of gene-specific reverse primers, R 5¢-AGAAAGCACG TAAGCTCCAGCCAA-3¢ for the detection of only the PRRSV (+) gRNA (which targets PRRSV ORF1 gene) and R 5¢-AGCATCTGGCACAGCTGATTGACT-3¢ for the detection of viral sg mRNAs (which targets the PRRSV ORF7 gene) were used. It is important to specify that with the ORF7 reverse primer, all the (+strand) ORF7 sequences are detected, which include the ORF7 sequence from the PRRSV viral genome and all the viral sg mRNA sequences, which explains its use to quantify genome transcription. The obtained cDNA was treated with 1.5 µg RNase A (Invitrogen) for 30 min at 37 C to remove the remaining RNAs, followed by inactivation of RNase A by heating at 95 C for 10 min. Overall, 2 µl of cDNA were amplified using the same reagents and conditions as described above. Primer pairs used for PRRSV ORF1 amplification were F 5¢-TG TGAGTTTGACTCGCCAGAGTGT-3¢ and R 5¢-TACAG TCTGCAACAATGCCAAGCC-3¢; and for PRRSV ORF7 were F 5¢-GCGGCAAGTGATAACCACGCATTT-3¢ and R 5¢-TGCTGCTTGCCGTTGTTATTTGGC-3¢. The Ct values obtained were transformed in PRRSV (+) gRNA and PRRSV sg mRNAs copies ml
À1
, for PRRSV genome replication and transcription quantification, respectively, based on a generated standard curve. First, PRRSV viral genome molecular weight was calculated using the PRRSV ATCC VR2332 reference strain complete viral genome sequence (GenBank accession number: EF536003) and a formula available from the Life Technologies website (www.lifetechnologies.com/ca/en/home/references/ambion-tech-support/ rna-tools-and-calculators/dna-and-rna-molecular-weightsand-conversions/). Afterwards, the PRRSV viral genome was purified from our virus stock and its concentration was determined. Then, the number of PRRSV viral genome copies was calculated. Thereafter, 10-fold serial dilutions of the PRRSV stock-purified RNA was realized and RT-qPCR assays were performed as described above to establish the standard curve. All experiments were repeated three times in duplicate. As internal controls, RT-qPCR for the mRNA detection of PPIA (in PAM cells) and B2M (in SJPL and MARC-145 cells) housekeeping genes was also performed on the same RNA sample preparations using the primers described above.
Western blot assays
Altogether, 4Â10 6 PAM and 5Â10 5 SJPL/MARC-145 cells were infected and incubated with or without the App culture supernatant. At 52 h p.i., 40 µg of total proteins from each sample were loaded and were fractionated by electrophoresis on 10 % (w/v) SDS-PAGE gels, then transferred onto a nitrocellulose membrane (Bio-Rad) using Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). Membranes were blocked with TBS-Tween 20 solution containing 5 % (w/v) BSA (Sigma-Aldrich) or 5 % (w/v) non-fat dry milk during a 2-3 h period at room temperature. Subsequently, they were labelled with a 1 : 1000 dilution of rabbit cofilin antibody (no. 3312, Cell Signaling Technology) and with a 1 : 2500 dilution of mouse monoclonal b-actin antibody (mAbcam 8226, Abcam) and incubated at 4 C overnight. Horseradish peroxidase-conjugated goat anti-rabbit IgG and horseradish peroxidase-conjugated goat anti-mouse (Thermo Scientific) at a dilution of 1 : 3000 were used as secondary antibodies. The protein bands were visualized using the SuperSignal West Dura Extended Duration Substrate (Thermo Scientific) in the FUSION-FX Chemiluminescence System (Montreal Biotech). The same membranes were mildly striped using the protocol described on the Abcam website (www.abcam.com/index.html?pageconfig= resource&rid=11353&source=pagetrap&viapagetrap=strip-pingforreprobing) and were re-probed with rabbit GAPDH monoclonal antibody (no, 5174) to confirm equal loading and with the rabbit phospho-cofilin antibody (no. 3311, Cell Signaling Technology), both at a dilution of 1 : 1000. All experiments were repeated at least two times.
Immunofluorescence assay (IFA) for the detection of PRRSV antigen and F-actin Cells were fixed at 52 h p.i., for 30 min at room temperature, with a 4 % paraformaldehyde (PFA) solution prepared as described previously [9] . Uninfected cells were used as a negative control. The IFA assay was performed as described previously [9] . Briefly, the fixed cells were washed with PBS and were permeabilized for 10 min with a PBS solution containing 1 % Triton X-100. Subsequently, the cells were washed with PBS-Tween 20 (0.02 %) and incubated for 30 min with PBS containing 0.2 % Tween 20 and 1% BSA. Then, the cells were incubated with the a7 rabbit monospecific antiserum (a specific anti-N PRRSV protein antibody) diluted 1/200 at 4 C overnight [27] . Finally, the cells were washed and incubated in 1/160 dilution of anti-rabbit specific antiserum FITC conjugated (Sigma-Aldrich) and in 1/40 dilution of Alexa Fluor 594 phalloidin (a high-affinity F-actin probe-conjugated) (Invitrogen) for 30 min at room temperature. Nuclei were stained with 4¢,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). PAM-stained cells were visualized by confocal laser scanning microscopy (Olympus FV1000 IX81). MARC-145 and SJPL cells were visualized using a DMI 4000B reverse fluorescence microscope (Leica Microsystems). Images of these cells were taking with a DFC 490 digital camera (Leica Microsystems).
PRRSV replication in the presence of cytochalasin D 2Â10 5 PAM, and 1Â10 4 MARC-145 and SJPL cells, were infected using protocols 1 and 2 but the App culture supernatant was replaced by 3 µM of cytochalasin D (SigmaAldrich). In total, 3 µM of cytochalasin D were used to make sure that PRRSV replication was inhibited because lower quantities (1-2 µM) were previously reported to inhibit PRRSV infection [28] . At 52 h p.i., the production of PRRSV infectious particles were quantified by the K€ arber method as previously described [9, 24] .
App culture supernatant antiviral activity against other PRRSVs PRRSV strains used in this experiment were PRRSV genotype I reference strain, Lelystad virus (LV) and two other genotype II pathogenic strains (FMV09-1155278 and FMV13-LMIVV). Thus, 1Â10
4 cells were infected with each virus using protocol 1. The infectious dose of each virus was calculated as described above. All experiments were repeated three times in duplicate.
Statistical analyses
A one-way ANOVA model, followed by Tukey's multiple comparison test (GraphPad Prism Version 5.03 software) was used to establish if statistically significant differences existed between infected or uninfected cells treated or not with the App culture supernatant in the viability and mortality tests. The same test was used to determine whether the viral titres in the presence or absence of cytochalasin D were statistically significant. This statistical test was also used to determine whether the App culture supernatant may modulate the expression of F-actin in treated and PRRSVinfected cells. A two-way ANOVA model, followed by Bonferroni post-hoc tests (GraphPad Prism), was performed to determine whether there was a difference in PRRSV replication/transcription between App culture supernatant-treated cells and untreated cells. Several t-test statistical analyses (unpaired t-tests) were also performed with PRRSV replication/transcription kinetic results at 4 h p.i. The same test was also used to determine if type I and type II IFN relative expressions were statistically different in App culture supernatant-treated cells compared to untreated cells. Moreover, t-test statistical analyses were also used to determine whether the App culture supernatant may modulate the b-actin mRNA expression in treated and PRRSV-infected cells compared to control cells. To establish if the App culture supernatant possesses an antiviral effect against different PRRSV strains, a two-way ANOVA model, followed by statistical analyses of Bonferroni post-hoc tests and t-tests (unpaired) were also performed. Differences between experimental groups were considered statistically significant with a P<0.05.
RESULTS
Impact of the App culture supernatant on cell viability and mortality The viability test showed no statistically significant differences between the negative control and the App culture supernatant-treated cells (Fig. 1a) . PRRSV-infected cells had the lowest cell survival compared to all other treatments. PRRSV-infected PAM cells treated with the App culture supernatant had a significantly higher cell survival (OD: 1.39±0.27) compared to App culture supernatant nontreated PRRSV-infected cells (OD: 1.03±0.21). Opposite results were obtained with the mortality test (Fig. 1b) . In fact, when PRRSV-infected cells were treated with the App culture supernatant, it significantly improved the mortality rate of the cells (43.12 %±3.23) compared to PRRSVinfected and untreated cells (59.19 %±3.04). In summary, both methods showed that the App culture supernatant did not affect PAM cell integrity and metabolism and had a positive effect on PAM cell survival when they are PRRSVinfected.
Type I IFN and IFN-g mRNA relative expressions in App culture supernatant-treated cells Specific RT-qPCR tests were performed to determine if the App culture supernatant induces the expression of type I and II IFN mRNAs in PAM cells because IFNs are known to be potent antiviral molecules against PRRSV infection [29] [30] [31] . The App culture supernatant only induced a small level of IFN-a mRNA expression, which was slightly increased compared to non-infected and non-treated PAM cells and had no modulation effect on IFN-b and IFN-g mRNA expression levels (Fig. 2) . PRRSV induced a significant increase in IFN-a and IFN-b mRNA relative expressions, i.e. 8.52±3.74 and 41 946±37 548 times more, respectively, compared to non-infected/non-treated cells (Fig. 2a, b) . Significant decreases in IFN-a and IFN-b mRNA relative expressions were observed in infected PAM cells treated with the bacterial supernatant (2.05±0.36 and 1100±2260, respectively) compared to PRRSV-infected cells alone indicating that the App culture supernatant had a major impact on PRRSV-infected PAM cells (Fig. 2a, b) .
PRRSV genome replication and transcription kinetics in the presence of the App culture supernatant In PRRSV-infected PAM cells, starting between 8 and 16 h p.i., an increase in (+) gRNA copies ml À1 was observed reaching a plateau at 32 h p.i. (Fig. 3a) . However, in PRRSV-infected and App culture supernatant-treated PAM cells, no increase in (+) gRNA copies ml À1 was detected. Moreover, in the presence of the App culture supernatant, a significant decrease of (+) gRNA copies ml À1 was observed from 28 to 52 h p.i. compared to 4 h p.i. Similarly, PRRSV sg mRNA copies ml À1 began to rise between 8 and 16 h p.i. in PRRSV-infected cells, reaching a plateau at 32 h p.i. while no increase of PRRSV sg mRNA copies ml À1 was observed in the presence of the App culture supernatant. A statistically significant decrease in sg mRNA copies ml À1 was observed from 24 to 52 h p.i., when compared with data at 4 h p.i., in PRRSV-infected and App culture supernatanttreated cells (Fig. 3b) . Similarly to PAM cells, an increase of (+) gRNA and sg mRNA copies ml À1 in PRRSV-infected SJPL cells was observed between 8 and 16 h p.i. while no increase was observed in PRRSV-infected cells treated with the App culture supernatant (Fig. 3c, d ). However, a significant increase of PRRSV (+) gRNA and sg mRNA copies ml À1 was observed in the presence of the bacterial supernatant in (+) gRNA and sg mRNA copies ml À1 from 38 to 52 h p.i. and from 24 to 52 h p.i., respectively, when compared to the data at 4 h p.i. Still, this increase was significantly lower compared to App culture supernatant nontreated cells, suggesting that the App culture supernatant antiviral effect is less efficient in PRRSV-infected SJPL cells compared to infected PAM cells (Fig. 3) . In MARC-145 cells, no significant difference was obtained between PRRSV-infected cells treated or not with the App culture supernatant in both genome replication and transcription assays (Fig. 3e, f) . This latest result was not surprising because it has been previously reported that the App culture supernatant is not able to inhibit the replication of the PRRSV IAF-Klop strain in infected MARC-145 cells [9, 24] . The early time p.i. results clearly indicate that the App culture supernatant inhibits PRRSV infection before the first cycle of PRRSV genome replication/transcription in both PAM and SJPL cells. In addition, similar results were obtained using both infection protocols (data not shown).
Actin cytoskeleton modulation in App culture supernatant-treated cells App has been previously shown to degrade actin in vitro [32] and PRRSV needs an intact actin cytoskeleton for cell infection and replication [5, 28] . To confirm the involvement of actin in the App culture supernatant antiviral effect, the b-actin mRNA transcription level and protein expression were determined in treated cells at 52 h p.i. As shown in Fig. 4(a, c) , the b-actin mRNA relative expression was lower in App culture supernatant-treated PAM and MARC-145 cells compared to untreated control cells. In addition, the b-actin mRNA relative expression was lower in PRRSVinfected and App culture supernatant-treated PAM cells compared to untreated control cells (Fig. 4a) . Subsequently, the b-actin protein expression level was slightly decreased in App culture supernatant-treated PAM cells compared to untreated control cells (Fig. 4d) . In SJPL cells, no modulation of b-actin mRNA and protein expression levels was observed (Fig. 4b, e) . Those results indicate that App culture supernatant modulation of the b-actin expression seems to be cell type dependent. Then, the polymerization status of actin (i.e. filamentous actin: F-actin) was evaluated since its polymerization state is part of an intact cytoskeleton. A decrease in F-actin fluorescence intensity was observed in App culture supernatant-treated PAM cells, but this decrease was more pronounced in PRRSV-infected cells treated with the App culture supernatant (Fig. 5a, b) . In SJPL cells, IFA also revealed a decrease in F-actin fluorescence intensity in App culture supernatant-treated cells compared to mock-untreated cells (Fig. 5c) . Interestingly, no marked difference was detected in regards to the F-actin expression level between App culture supernatant-treated and untreated MARC-145 cells.
IFA results showed a decrease in F-actin level in App culture supernatant-treated cells, suggesting that actin is depolymerized. Moreover, our previous results obtained with a commercial antibodies microarray (Kinexus KAM-850) indicated that the App culture supernatant modulates the cofilin expression level in PAM-treated cells (Table S1 , available in the online version of this article). Cofilin active form (i.e. dephosphorylated) is known to provoke F-actin depolymerization. Thus, it was important to determine the amount of total cofilin versus phosphorylated cofilin (Pcofilin) in App culture supernatant-treated and PRRSVinfected cell lines. Western blot analyses revealed that the total cofilin relative density in PRRSV-infected PAM cells treated with the App culture supernatant was higher compared to PRRSV-infected cells alone, to App culture supernatant-treated cells and to negative cells (Fig. 6a) . Interestingly, the relative density of P-cofilin was lower in infected PAM cells treated with the bacterial supernatant and also in PRRSV-infected cells compared to the other experimental groups (Fig. 6a) . Since total cofilin was significantly increased and P-cofilin was significantly lower in infected PAM cells treated with the bacterial culture supernatant, then it is logical to conclude that there is relatively more active cofilin in this experimental group compared to other groups. In SJPL cells, there was a slight increase in total cofilin protein level in App culture supernatant-treated cells compared to the other treatments (Fig. 6b) . No difference between control SJPL cells, PRRSV-infected SJPL cells alone and App culture supernatant-treated SJPL-infected cells were observed, which may explain why the App culture supernatant antiviral effect seems lower in SJPL cells compared to PAM cells (Fig. 6b) . However, like in PAM cells, P-cofilin levels were lower in infected SJPL cells treated with the bacterial culture supernatant and also in PRRSVinfected cells alone compared to the other experimental groups while higher levels were observed in SJPL cells treated with the bacterial culture supernatant compared to mock-treated SJPL cells (Fig. 6b) . In MARC-145 cells, the total cofilin protein levels slightly increased only in PRRSVinfected cells (Fig. 6c) . In a surprising way, it was observed that in infected MARC-145 cells treated with the App culture supernatant there was more P-cofilin than in the other experimental groups, which may explain why the App culture supernatant do not have an antiviral effect against PRRSV in infected MARC-145 cells.
Infectious viral particle production in PRRSV-infected cells treated with cytochalasin D
The cytochalasin D microfilament disrupting compound effect on PRRSV infection in PAM and MARC-145 cells is already known [5, 28] . However, it was important to test its efficiency in our experimental conditions and on cells that have not been previously tested, i.e. the SJPL cell line. For this purpose, all cell lines were infected and treated with 3 µM of cytochalasin D using both infection protocols. The (Fig. 7a) . Cytochalasin D completely blocked PRRSV infection in SJPL cells with at least a 500 000 times infectious titre reduction (P<0.05) (Fig. 7b) . Cytochalasin D was not able to inhibit PRRSV infection in MARC-145 cells (Fig. 7c) . Of note, in PAM and SJPL cells, there is a complete inhibition of PRRSV infection in the presence of cytochalasin D because the number of infectious virions obtained in infected cells treated with this compound was lower or equal to the infectious PRRSV particles measured at 4 h p.i., which is considered to be the number of particles attached and/or entered into the cells (Fig. 7a,  b) . It is noteworthy that similar results were obtained with both infection protocols, i.e. with cytochalasin D added 2 h prior to or 4 h after PRRSV infection (data not shown). These results clearly demonstrate that cytochalasin D, like the App culture supernatant, inhibits PRRSV infection in PAM and SJPL cells, but not in MARC-145 cells.
App culture supernatant antiviral effect against different PRRSV strains
Results demonstrated that the number of infectious virions in the LV PRRSV strain-infected cells treated with the App culture supernatant was significantly lower (107 to 1202 times lower) than in LV-infected cells alone in all cell types (P<0.05) (Fig. 8) . Viral titres obtained with the FMV13-LMIVV PRRSV strain demonstrated that the bacterial culture supernatant significantly reduces the number of infectious virions compared to FMV13-LMIVV-infected cells alone (P<0.05) (Fig. 8) . Nonetheless, the App culture supernatant antiviral power against the FMV13-LMIVV strain in PAM cells was the smallest, the amount of PRRSV was 13.49 times lower when PRRSV-infected cells were treated with the App culture supernatant (Fig. 8a) . Viral titres obtained with the FMV09-1155278 PRRSV strain demonstrated that the App culture supernatant significantly reduces the number of infectious virions compared to infected cells alone (P<0.05) (Fig. 8) . Overall, the App culture supernatant antiviral efficacy varied between virus strains and between infected cell models. Of note, the App culture supernatant antiviral effect tends to be lower in infected MARC-145 cells compared to the two other cell models (Fig. 8d) .
DISCUSSION
The newly discovered antiviral activity of the App culture supernatant against PRRSV was shown to be effective in the SJPL and PAM cells but not in MARC-145 cells [24] . It was also previously demonstrated that other viruses such as equine herpes virus type 1, swine influenza H1N1 and H3N2 infection could be inhibited by the App culture supernatant in the SJPL cells but to a significantly much lower extent compared to PRRSV. Interestingly, the bovine adenovirus 3, bovine herpes virus type 1 and bovine viral diarrhea virus type 1 infections were not affected by the App culture supernatant, indicating that SJPL cells are metabolically active and able to support the growth of several other viruses. Since the impact of the App culture supernatant on PAM cell viability and mortality was unknown, it was important to establish the PAM cell status following App culture supernatant treatment. Results indicate that the bacterial supernatant did not induce cell death since similar results were obtained between the untreated control and App culture supernatant-treated cells (Fig. 1) . In addition, it was observed that in PRRSV-infected cells treated with App culture supernatant antiviral, there was a significant increase in cell survival and a significant decrease in mortality rate compared to App culture supernatant non-treated PRRSV-infected cells. This PAM cell survival increase can be the direct consequence of the lower PRRSV replication induced by the antiviral effect of the App culture supernatant. Taken together, these results demonstrated that App culture supernatant-treated PAM cells are viable, metabolically active and that the observed antiviral effect of the bacterial supernatant is not due to cell mortality. In order to identify the App culture supernatant antiviral mechanism, the mRNA expression of type I and II IFNs was determined because these cytokines are very important for the host antiviral immune response [33, 34] , even though it is well known that PRRSV has developed strategies to evade their antiviral effects [35] [36] [37] [38] . It was observed that the App culture supernatant induces a basal or slight increased mRNA relative expression of IFN-g and IFN-a compared to untreated cells (Fig. 2) , indicating that the App culture supernatant antiviral effect is not mediated via the induction of those cytokines. L evesque and collaborators also observed that the bacterial supernatant did not induce type I IFN expressions in the SJPL cell line [24] . However, an induction of type II IFN expression was detected in SJPL cells, which suggests that App culture supernatant antiviral effect might be via the induction of IFN-g but no modulation of IFN-g mRNA expression was observed in App culture supernatant-treated PAM cells. These results suggest that the App culture supernatant antiviral effect may occur via other mechanisms that are cell type dependent. Moreover, it was demonstrated that mRNA relative expression of type I IFN was decreased in PRRSV-infected PAM cells treated with the bacterial supernatant compared to PRRSV-infected cells alone. Type I IFN mRNA decrease can be the direct effect of PRRSV replication inhibition by the bacterial antiviral effect or by a component within the App culture supernatant. It is noteworthy that RNA-Seq experiments will soon be carried out to better establish the impact of the App culture supernatant over the modulation of cell mRNA expression.
All stages of the virus replication cycle are dependent on host cell machinery. For instance, (1) PRRSV entry occurs via receptor-mediated endocytosis and this process was demonstrated to be microfilament dependent [5, 28] ; (2) PRRSV uncoating is known to be dependent on acidic pH of the early endosomes and also involved cellular proteases [5, 39, 40] ; and (3) PRRSV genome replication/transcription is believed to be produced in autophagosome-like doublemembrane vesicles [41, 42] . In order to identify at which PRRSV replication cycle step the bacterial antiviral effect occurs, the PRRSV genome replication and transcription were evaluated. Results clearly demonstrate that the App culture supernatant antiviral effect against PRRSV takes place prior to the first cycle of genome replication and transcription. The fact that during the first 4 to 8 h p.i. similar results were obtained using both PRRSV infection protocols (Fig. 3) , indicated that at least PRRSV attachment to cells is not inhibited by App culture supernatant treatment because titres were determined by the K€ arber method and were expressed in TCID 50 ml À1 . The horizontal dotted lines represent the intracellular infectious PRRSV particles detected at 4 h p.i. Values are presented as the ±SD. When two sets of data are labelled with superscripts of different letters or when only one set is labelled with a superscript, it indicates that these two sets of data are statistically different (P<0.05). Depending on the cell type studied, this experiment was performed at least in quadruplicate.
it is well known that this process in PAM reaches a maximum at 1 h p.i. [5] . Overall, the results clearly indicate that the App culture supernatant antiviral effect against PRRSV takes place at least during the entry, uncoating or during the formation of the replication/transcription complex. At the moment, it is not possible to specify at which of these three virus replication steps the App culture supernatant antiviral effect occurs. Otherwise, the App culture supernatant antiviral effect seems more efficient in PAM cells compared to SJPL cells. The gRNA replication was entirely inhibited in PAM cells whereas, in SJPL cells, a small but statistically significant increase of (+) gRNA and sg mRNA copies was observed over time (Fig. 3) , suggesting that in SJPL cells, few PRRSV particles can achieve a complete replication cycle. These findings can be explained because both cell types are phenotypically different. In fact, a recent study performed by Provost and colleagues demonstrated that PRRSV receptors contained in both cell types are different [9] . Further studies should be conducted in order to identify PRRSV entry mediators and to investigate, in detail, the PRRSV replication cycle in the new SJPL cell infection model. At the moment, there is no data to explain why the MARC-145 cellular response in regards to App culture supernatant antiviral action is different. The major difference known between MARC-145 and PAM cells in regards to the PRRSV replication cycle is the virus entry into the cell. PRRSV entry mediators in PAM and MARC-145 cells are different, confirming that virus entry differs between the two cell types. For instance, in MARC-145 cells the sialoadhesin is absent [6] and the sialic acids present in the virion are not essential for infectivity [43] . It was also reported that cholesterol is critical for PRRSV entry in MARC-145 cells and also suggests that PRRSV entry could be via a lipid-raftdependent endocytosis [44, 45] . Therefore, the MARC-145 cell-adapted IAF-Klop strain can probably use a completely different entry mechanism in both cell types, which makes the PRRSV IAF-Klop strain resistant to the App culture supernatant antiviral effect in MARC-145 cells. However, this observation might be strain-specific since the results in Fig. 8(c) show that the App culture supernatant possesses an antiviral activity in MARC-145 cells against three other genetically different PRRSV strains. More experiments are needed to elucidate this virus strain effect.
Garcia-Cuellar and colleagues have demonstrated that an
App secreted 24 kDa Zn-metalloprotease is able to degrade actin protein in vitro [32] . Moreover, several reports have revealed the important role of actin cytoskeleton on PRRSV infection [5, 6, 28, 46] . Therefore, based on these previous findings, it is more likely that the App culture supernatant antiviral effect could be modulated through actin cytoskeleton. Interestingly, an antibodies microarray (Kinexus) revealed that cofilin 1 and LIMK1 (proteins involved in actin pathway) were modulated by PRRSV and the App culture supernatant (Table S1 ). Consequently, the actin cytoskeleton modulation was investigated. It has been established that cofilin severing activity induces F-actin free ends accessible for actin polymerization and depolymerization [47, 48] . Cofilin has two statuses: unphosphorylated and phosphorylated. Its active form (i.e. unphosphorylated cofilin) is able to bind F-actin and promote its depolymerization [47] . LIMK is assumed to deactivate cofilin through its phosphorylation [48, 49] . Actin cytoskeleton was demonstrated to be involved in many RNA and DNA viruses' replication cycle [50] [51] [52] [53] . As an example, human immunodeficiency virus (HIV) has been shown to decrease P-cofilin [54] . It was demonstrated that cofilin activation and actin dynamics are very important for the post-entry process of HIV of resting T cells. Moreover, Yoder et al. [54] have reported that it was the attachment of HIV to the cell surface of the chemokine coreceptor CXCR4 that subsequently initiates the signalling toward cofilin activation and actin depolymerization. This process allows the resting T cells to be permissive to HIV infection. Therefore, a similar mechanism may also be involved in the PRRSV post-entry process since our data indicated that the PRRSV IAF-Klop strain has induced a significant decrease of P-cofilin in all tested three cell types (Fig. 6) . In fact, during PRRSV infection, the microfilaments are a critical component necessary for PRRSV primary and secondary infection [5, 28] . Interestingly, there was more active cofilin in App culture supernatant-treated infected PAM cells compared to other experimental groups (Fig. 6a) . This finding suggested a possible F-actin modulation, which was confirmed by IFA. The confocal microscopy revealed that F-actin fluorescence intensity was decreased in App culture supernatant-treated cells, but its decrease was more pronounced in App culture supernatant-treated infected PAM cells (Fig. 5a, b) . A previous report suggests that a negative correlation exists between the F-actin expression level and PRRSV infection [28] , indicating that PRRSV decreases F-actin to favour its infection. Therefore, it is possible that PRRSV modulates the amount of F-actin that is needed for its infection but when certain low and high thresholds are exceeded, PRRSV infection is compromised. For that reason, it is suggesting that when PRRSV-infected cells are treated with the App culture supernatant, there is an increase of active cofilin that will subsequently induce F-actin depolymerization and thereafter PRRSV infection inhibition. Interestingly, a decrease of Pcofilin combined with a reduction of F-actin in App culture supernatant-treated SJPL cells suggests that the antiviral mechanism in both PAM and SJPL cells might be similar at some points. In PRRSV-infected MARC-145 cells treated with the bacterial antiviral, more P-cofilin (inactive form) was detected compared to other experimental groups (Fig. 6 ). In addition, there was no F-actin depolymerization in the presence of the App culture supernatant in MARC-145 cells (Fig. 5c) . Therefore, since the App culture supernatant cellular response in MARC-145 cells differs from PAM and SJPL cells, these results highly suggest that the App culture supernatant cellular target is cofilin. Moreover, the different App culture supernatant effects observed between treated cell lines could be explained by the cofilin/b-actin ratio as previously reported by Bamburg and Bernstein [55] . The cofilin/b-actin ratio plays a major role in the polymerization state of F-actin [55] . In fact, low cofilin/b-actin ratios lead to F-actin polymerization and high cofilin/b-actin ratios promote depolymerization of F-actin. Combination of the Western blot results of Figs 4 and 6 show that in control PAM cells, the cofilin/b-actin ratio was relatively low (0.53, data not shown), thus F-actin was polymerized. In App culture supernatant-treated PAM cells, the cofilin/b-actin ratio was slightly higher (0.94, data not shown) and therefore some F-actin was depolymerized compared to mock-treated cells. In PRRSV-infected PAM cells, the cofilin/b-actin ratio was similar to App culture supernatant-treated cells and Factin was also partially depolymerized. In App culture supernatant and PRRSV-infected PAM cells, the cofilin/b-actin ratio was relatively higher (1.23, data not shown) compared to all other treatments, thus F-actin was found to be even more depolymerized as shown in Fig. 5(a, b) . In SJPL cells, the ratio of cofilin/b-actin in App culture supernatanttreated cells (1.21, data not shown) was higher compared to mock-treated cells (1.03, data not shown) and this correlates with our observation of lower levels of polymerized F-actin (Fig. 5c) . In MARC-145 cells, cofilin/b-actin ratios were similar between untreated and App culture supernatanttreated cells, supporting also the observation that the same polymerization state of F-actin was observed between these two experimental groups as shown in Fig. 5(c) . Furthermore, those results suggest that the F-actin depolymerization phenomenon in PAM and SJPL cells was not related to the metalloprotease secreted by App that degrades b-actin in vitro [32] , but rather to cofilin [48] .
The different response that was observed between PAM and MARC-145 cells could be that inflammasome might be involved in the App culture supernatant effect. Inflammasomes are receptor and sensor proteins from the innate immune system that regulate the activation of caspase-1 and induce inflammation in response to infectious microbes, such as bacteria and viruses [56] . In macrophages, PRRSV infection has been demonstrated to induce capsase-1 and inflammasome activation [57, 58] . Moreover, it was shown that the actin polymerization state also plays a major role in inflammasome activation [59] . It was also proposed that disruption of F-actin polymerization might activate the inflammasome [60] . Since no modulation in F-actin was observed in App culture supernatant-treated MARC-145 cells (Fig. 5c) and an important change in actin polymerization state was observed in App culture supernatant-treated PAM and SJPL cells (Fig. 5) , then it could suggest the involvement of caspase-1 and inflammasome into the App culture supernatant antiviral effect. However, other experiments are needed to be conducted to confirm this hypothesis.
In order to confirm the involvement of actin cytoskeleton in the App culture supernatant antiviral effect, the effect of cytochalasin D (a drug that destabilizes actin filaments) on PRRSV replication was determined. The use of this drug has been a valuable tool for investigating the roles of actin filaments in cellular processes and in viral pathogenesis [5, 28, 53, [61] [62] [63] [64] [65] . Cytochalasin D was able to inhibit PRRSV replication in PAM and SJPL cells, but not in MARC-145 cells, such as the App culture supernatant (Fig. 7) . In this study, cytochalasin D was added a few hours before or shortly after PRRSV infection and like the App culture supernatant, it was able to inhibit PRRSV replication indicating that PRRSV was able to at least attach to the target cells (data not shown). Therefore, these results highly suggest that the App culture supernatant probably inhibits PRRSV infection during its entry via clathrin-mediated endocytosis, since it is well known that this process is actin cytoskeleton dependent [5, 28, [66] [67] [68] . Conflicting data have been previously reported in regards to the antiviral effect of cytochalasin D against PRRSV in infected MARC-145 cells. In fact, Cafruny and collaborators have demonstrated that cytochalasin D at 1-2 µM concentration was able to inhibit PRRSV primary infection in MARC-145 cells [28] . However, in the present study, a higher dose of cytochalasin D (3 µM) was used, and with this experimental condition, the PRRSV replication was not inhibited in infected MARC-145 cells. It is noteworthy that this discrepancy can also be the consequence of having used different PRRSV strains in each study. Several studies have demonstrated that the PRRSV isolates' adaptation process in MARC-145 cells generates genetic changes, including deletions, insertions or substitutions and is characterized by higher titres, faster growth kinetics that make the newly adapted isolates less virulent than the wild-type [69] [70] [71] [72] [73] . Then, it is possible that the PRRSV IAF-Klop strain can use an entry mechanism that is actin cytoskeleton independent, in order to successfully replicate in the MARC-145 cells, which perfectly explains why the App culture supernatant antiviral effect is inefficient in MARC-145 cells (Fig. 8c) . Following this hypothesis, the App culture supernatant antiviral effect against other PRRSV strains was investigated. Interestingly, the replication of three PRRSV strains, which are classified within two different species [1] , was significantly inhibited by the App culture supernatant whereas no antiviral effect was detected against the IAF-Klop strain in this cell model, indicating that the efficiency of the App culture supernatant antiviral effect is strain dependent in MARC-145 cells (Fig. 8) . This dependence can be due to differences in the PRRSV strains' entry mechanisms in MARC-145 cells as previously commented. Further studies need to be conducted in order to ascertain this hypothesis. Of note, the App culture supernatant antiviral efficiency tends to be lower in infected MARC-145 cells compared to infected PAM and SJPL cells (Fig. 8d) . Perhaps because PRRSV strains used in this study are highly adapted to replicate in MARC-145 cells (i.e. this cell line is used for virus stock production and three out of the four PRRSV strains were isolated from clinical samples using this cell line).
In conclusion, this study clearly demonstrated that the App culture supernatant inhibits PRRSV infection prior to the first cycle of PRRSV genome replication/transcription in PAM and SJPL cells, probably via the activation of cofilin, which can provoke actin depolymerization and subsequently this phenomenon might affect PRRSV endocytosis. Further studies are in progress in order (1) to confirm that the App culture supernatant affects PRRSV entry by endocytosis in PAM cells and (2) to find the active metabolite(s) present in the App culture supernatant that is responsible for the antiviral effect.
